Vogl S E, Schoenfeld D A, Kaplan B H, Lerner H J, Horton J, Creech R H, Barnes L E
Cancer. 1982 Dec 1;50(11):2295-300. doi: 10.1002/1097-0142(19821201)50:11<2295::aid-cncr2820501113>3.0.co;2-4.
Patients with advanced, incurable squamous cancer of the head and neck were randomly assigned to treatment with weekly methotrexate alone or methotrexate with Corynebacterium parvum given subcutaneously in weekly bilateral doses in sites around the neck. The addition of C. parvum did not alter the response rate, response duration, survival (either median or long-term) or severity of toxic effects compared to treatment with methotrexate alone. Response rates were higher for patients without distant metastases, ambulatory patients, and those younger than age 65 years. Median survival was improved for responders to chemotherapy and for those initially ambulatory. C. parvum given subcutaneously has no place in the treatment of far advanced cancer of the head and neck.
单独每周使用甲氨蝶呤，或甲氨蝶呤联合短小棒状杆菌，后者以每周双侧剂量皮下注射于颈部周围部位。与单独使用甲氨蝶呤治疗相比，添加短小棒状杆菌并未改变缓解率、缓解持续时间、生存率（中位生存期或长期生存率）或毒性作用的严重程度。无远处转移的患者、可走动的患者以及年龄小于65岁的患者缓解率更高。化疗有反应者和最初可走动的患者中位生存期有所改善。皮下注射短小棒状杆菌在晚期头颈部癌的治疗中没有地位。
